Skip to Content
  • A Look at Antibody Therapies

    Since we were just talking about antibody therapies in immuno-oncology, here’s a timely column by Bruce Booth at LifeSciVC on antibody therapies in genera… Read More
  • Turmoil in Immuno-oncology

    Immuno-oncology! It’s such a big deal, let’s just do what everyone in the field is doing and call it “IO”. The recent successes in this… Read More
  • There Are Failures, You Know

    This exact point came up around here when we last discussed FDA reform, so it’s good to see it made at length in the New England Journal of Medicine. Reme… Read More
  • Kite’s Latest News

    Readers will surely recall the problems that surfaced last year with Juno’s CAR-T cell therapy program. There were a number of patient deaths, and worried… Read More
  • Zafgen’s Second Act

    F. Scott Fitzgerald was a very good writer, but one of his most famous lines is about as wrong as it can be. It’s actually a cliché to point out the com… Read More
  • Neurotrope: A Shameful PR Stunt

    There was some Alzheimer’s news the other day, but it wasn’t actually about Alzheimer’s. Not very much. It was more about hype, press releases… Read More
Page 3 of 4712345...102030...Last »